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Abstract
Ultrasound guided brachytherapy for the treatment of prostate cancer has become a
routine treatment option, due to many benefits including patient recovery and dose
localisation [1]; however it is not clear whether the standards which govern the image
quality for these systems are adequate. Upon review of the recommended standards for
ultrasound systems used in prostate brachytherapy procedures, the recommended tests do
not appear to be specific to the clinical application of ultrasound guided prostate
brachytherapy. Rather they are generic and similar to those recommended for other clinical
applications such as general abdominal scanning [2].

Furthermore, there is growing

evidence that these tests should be specific to the clinical application [3][4] in order to gain
meaningful data about the performance of the system for the application, and also to detect
clinically relevant changes in quality control results. An additional problem is that there are
no clinically relevant test phantom recommended for the quality assurance of ultrasound
systems used in prostate brachytherapy. The image quality for this application of ultrasound
1

needs to be monitored to ensure consistent levels of confidence in the procedure. This
paper reviews the currently recommended test guidelines and test phantoms for ultrasound
systems used in prostate brachytherapy from the different standard bodies and professional
organisations. A critical analysis of those tests which are most reflective of the imaging and
guidance tasks undertaken in an ultrasound guided prostate brachytherapy procedure will
also be presented to inform the design of a TRUS quality assurance protocol.
Key words: Trans-rectal ultrasound (TRUS), quality assurance, image quality, test
phantoms, brachytherapy
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Introduction
Prostate cancer is the second most frequent cause of cancer in European men [5], with
similar incidences worldwide. The prognosis for the disease, when diagnosed and managed
early, is a three-year survival rate of 94% [6]. Treatment for the disease is dependent on the
malignancy and the stage of the disease. Throughout the management of the disease,
diagnostic imaging and in particular, ultrasound imaging play a vital role from diagnosis to
medical intervention [6]. Ultrasound imaging is a non-ionizing real-time technique that can
provide information about the size, morphological and acoustic characteristics of tumour as
well as its application in the guidance of interventional procedures such as a biopsy,
treatment planning and treatment delivery. It is clear, that ultrasound is a valuable imaging
modality in the treatment of prostate cancer, but it is of paramount importance that reliable
and consistent clinical information is provided to adequately treat the patient, and to avoid
any complications associated with administering the incorrect dose of radiation, such as
repeat procedures, incontinence and radiation proctitis. The importance of quality assurance
in prostate brachytherapy centres and the implications of a poor quality brachytherapy
service was highlighted by a report that reviewed the performance of prostate
brachytherapy in the treatment of prostate cancer during the seven year period of 2002–
2008 in one treatment centre. [7] The report identified many errors, including suboptimal
implants resulting in some patients requiring a second intervention and high toxicity causing
proctitis in others. The report indicates a lack of training and good quality assurance was
responsible for the errors.
Therefore, the ultrasound system needs to be operating optimally and maintained to
ensure that any degradation in image quality is detected and not mistaken as a clinical
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anomaly. The quality assurance process should establish the accuracy of the guidance
through commissioning and routine testing, detect faults within the scanner with regular
quality assurance and should be task specific, relevant to the process of delineating disease.
The guidance and recommendations which are currently available to inform a programme of
quality assurance for trans-rectal ultrasound (TRUS) imaging, and the tests phantoms that
are available, will be reviewed to determine their efficacy and to inform the design of a
TRUS quality assurance protocol.

Brachytherapy
Ultrasound guided brachytherapy involves the use of (TRUS) imaging to guide the placement
of radioactive material into the prostate. There are two methods of brachytherapy that are
available for the treatment of prostate cancer; high and low dose rate treatments. The high
dose rate treatment can be delivered in a number of fractions or as a complimentary
therapy to external beam treatment, and involves the introduction of a high dose
radioactive source, usually a wire, into the prostate through a catheter where it is left for a
short period of time and removed.. Treatment centres that employ low dose rate
brachytherapy implant radioactive material, seeds, into the prostate where they are left to
decay to a background level of radioactivity overtime. This type of radiotherapy treatment,
similarly to external beam radiotherapy, is planned and pre-treatment imaging is performed
using ultrasound imaging. These pre-treatment ultrasound images are used to make volume
measurements of the prostate and determine the number of seeds required to deliver the
required dose for the procedure. During treatment, volume measurements are also made
and visualisation of the prostate and surrounding structures is important for real-time image
guidance of the seeds to desired locations for optimal dose delivery. The information
acquired from ultrasound images before and during the treatment is used to make
4

important clinical decisions and so the value of quality assurance testing of the ultrasound
systems used to make these decisions becomes evident.

Quality assurance
Quality Assurance Guidance and Recommendations
Professional bodies such as the Royal College of Radiologists and the Society and College of
Radiographers recommend ultrasound Quality Assurance (QA) programmes as part of the
overall governance of ultrasound examinations [8][9]. The goal of a QA programme for
ultrasound systems is to ensure consistent and acceptable levels of system performance,
detect faults and document any system degradation over time. The nature of an ultrasound
examination means the clinical user makes these decisions in real-time and only a small
number of frames are available for review after the decision has been made [10]. A highquality ultrasound procedure requires both a high-quality system and an experienced user.
The user is expected to understand the equipment settings and their impact on image
quality and, to identify when there are issues with the system and the images produced.
Periodic testing is imperative in the assurance of optimum and consistent system quality
[11]. Generally, measurements are made and recorded, and baseline values are determined
with tolerances and action levels to monitor the systems performance. However, it has been
shown that the current QA guidelines may not be relevant to the clinical image quality, and
there have been incidences where ultrasound systems have had major faults and were still
in clinical use [3][10]. Hangiandreou et al. 2011, found that in a four year study of 45
ultrasound systems, 187 issues were detected with the scanner equipment that was in
clinical use [12].
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The technological advances in ultrasound technology and the increased use of ultrasound as
a diagnostic tool, puts an increased demand on the QA programmes. The clinical significance
of test parameters will vary with the application. The changes in the imaging parameters
need to be related to clinical task and efficacy, and currently the systems of QA do not make
this connection [13][3][14]. While there has been work carried out to remove the subjective
element of the testing procedures and to automate the process using software
[15][16][17][18] , the relevance of the QA parameters for each specific application must be
considered. Specifically, it is important to link quality assurance parameters with the clinical
view of image quality in order to establish what degradation in clinical image quality affects
clinical diagnosis or management; this may be achieved through the development of more
clinically relevant rest phantoms or task-specific test phantoms.
Quality assurance of ultrasound systems is essential to ensure repeatable and reliable image
quality. Professional bodies such as the Institute of Physics and Engineering in Medicine
(IPEM), the American institute of Ultrasound in Medicine (AIUM), the European Federation
of Societies for Ultrasound in Medicine and Biology (EFSUMB) and the American Association
of Physics in Medicine (AAPM), all recommend quality assurance programmes for
ultrasound systems to ensure consistent quality of ultrasound images [11][19][20][21]. Each
body identifies the need for a testing schedule with regular test intervals, and
documentation to monitor and continually assess the equipment performance. While there
is some variation in the recommended frequency of the QA tests between the professional
bodies, there seem to be at least three distinctive levels of testing that they recommend as
illustrated in table 1 [22].
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The first level of tests “User/Operator tests” are basic intuitive observations to ensure the
ultrasound system is operating normally. These tests are quick and provide a good
indication of obvious technical issues. The second level of tests “Technical tests” are
recommended predominantly for QA and acceptance purposes. These are tests that are
carried out when a new machine is accepted into a department and then at least annually, if
not biannually. At acceptance testing, the baseline values are determined and the
professional bodies provide guidelines on these values. Then these baselines are considered
and tolerances are determined to ensure that at each testing interval the machine is
operating at an acceptable level. The “Advanced tests” are not regularly performed;
generally only at acceptance testing or after significant repair or changes to the machine.
These tests assess characteristics of the system that are very unlikely to drift, and are also
monitored through other QA parameters through the periodic testing.
As well as recommended testing schedules, professional bodies such as the AAPM provide
guidance on the suitable tolerance levels for ultrasound systems [20], and Task Group 128
[2] also provide details on suitable tolerances for TRUS systems used in prostate
brachytherapy. Details of these tolerances are listed in table 2.

Another crucial element of the quality assurance process, are the test phantoms used to
assess the image quality. Some QA tests do not require a test phantom such as image
uniformity and noise tests [11], but test phantoms are important for a number of other
aspects of image quality. There are numerous test phantoms commercially available with
general ultrasound QA in mind. These test phantoms are designed with tissue mimicking
materials that have been designed to have the same speed of sound as the average of soft
7

tissue in the body, 1540m/s, and similar attenuation and backscatter values; the recent
IPEM Report 102 provides a comprehensive list of the commercially available test phantoms
[11]. These test phantoms all have similar generic targets included for annual QA tests,
namely the technical tests outlined in Table 1. These tests phantoms have been designed to
assess general image quality parameters and are largely developed with no specific clinical
application of ultrasound in mind. While there are commercially available test phantoms
that have been constructed to assess the image quality for the ultrasound systems used
during brachytherapy procedures, their design is inadequate as they do not include clinically
relevant targets to sufficiently test the ultrasound system for this specific application; of
prostate brachytherapy [2].

Quality Assurance in Brachytherapy
There are specific recommendations from the AAPM [2] that outline the parameters that
need to be considered specifically for ultrasound guided prostate brachytherapy and
suggest some key features for a test phantom for this application. However, like the other
recommendations, they are heavily based on the recommendations made for the general
application of ultrasound. In TRUS guided brachytherapy the system is used for guidance in
intervention and therefore, the quality assurance for this procedure should reflect this
application.
The resolution of the Ultrasound system used in prostate brachytherapy system is critical in
all three dimensions when identifying the prostate boundary, as well as the implanted seeds
and the needle. The guidelines state that axial and lateral resolutions, as well as slice
thickness, all affect the resolution, and even though they can be assessed separately it is
their overall contribution to the resolution that affects the image [2]. While this is the case
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the guidelines go on to ignore slice thickness and do not recommend evaluating partial
volume effects in the testing protocol.
The sensitivity of the system is determined by the depth of penetration, and in particular
the depth at which low contrast objects can be detected. The signal-to-noise ratio (SNR)
impacts this measurement such that a decrease in the SNR will make it difficult to visualize
the prostate [2]. Low contrast detectability is of paramount importance in prostate
brachytherapy ultrasound systems. The delineation of the prostate from the surrounding
tissue is critical in the area and volume measurements required in the treatment planning
for the brachytherapy procedure. It has been shown that for low contrast objects the
diameter for threshold detection is dependent on the target contrast, while at higher
contrasts the diameter is only weakly dependant on the target contrast [23][15]. Therefore,
it is vital to challenge the ultrasound systems contrast detectability at low contrasts and
varying sizes.
Area and volume measurements are of particular importance to the brachytherapy
procedure as these measurements are involved in the dosimetry calculations, used preoperatively, and during the procedure for the placement of the brachytherapy seeds. To
perform this analysis the AAPM guidelines suggest that a spherical test object with known
dimensions be used with a moderately high-contrast [2]. Prostate contouring and
delineation has been reported to suffer from inter-observer variations on both the TRUS
images and on post-operative CT imaging[24]. Lee et al. 2002 presents the results of a case
study of ten patients, and found that the ICC of 0.639 for the volume of the prostate was
good but the two dosimetric quantifiers D90 the minimal dose received by 90% of prostate,
and V100 the percentage of prostate volume receiving 100% of prescribed minimal
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peripheral dose, to be poor at ICC 0.275 and ICC 0.345 respectively[25]. The prostate’s
contrast in an ultrasound image makes it difficult to outline the gland from the surrounding
tissue[2]. Sandhu et al. demonstrated an improvement in prostate volume using tissue
harmonic imagining compared to conventional B-mode imagining in both a phantom and a
patient study [26][27]. Improvements in tissue differentiation that were associated with
tissue harmonic imaging improved the prostate contour and thereby, the corresponding
volume estimates. Therefore, an object such as that described by the AAPM would not
sufficiently challenge the ultrasound system and test its capabilities for the prostate
brachytherapy application. The accuracy of the volume measurement and the ability to
delineate a poorly defined border should be addressed independently.
Another unique feature to the application of ultrasound in the prostate brachytherapy
procedure is the grid and stepper system. The TRUS probe is placed in a rig mounted with a
stepper that is manually manipulated to introduce the probe into the rectum in specific
increments. The grid is used to align the needles, which are used to introduce the seeds into
the prostate, to specific locations represented on the ultrasound system. Ensuring that the
grid is aligned to the grid displayed on the image is imperative in the successful treatment of
patients; the seeds are distributed inside the prostate to ensure optimal dose distribution to
the prostate while sparing organs at risk such as the bladder and the rectum.

Test phantoms
Quality assurance test phantoms are an important part of an extensive and effective QA
programme. A good test phantom should be clinically relevant and be designed to assess
the ultrasound system in the context of the clinical application, and furthermore, be capable
of detecting issues before they have a clinical impact. Image quality refers to the aspects of

10

the image which are expected to impact the diagnostic capability of the system [11]. The
factors that affect the image quality and diagnosis for one application will differ to another,
and it is important to identify these factors and design a test phantom to ensure that these
image quality parameters are examined [3][28][29]. There are several test phantoms
commercially available to assess image quality, as well as specific test phantoms designed
for individual applications. Key features of a test phantom include clinically relevant targets
and contrasts. Some of the most common targets that are included in test phantoms are
targets at specific depths and spacing that can be used to assess the distance calibration and
the spatial resolution. However, the majority of these test phantoms do not include targets
for slice thickness assessment therefore, artefacts such as the partial volume effect cannot
be evaluated which impacts needle tip visualisation (Ref). A homogenous known material
such as the background of a test phantom can be used to assess the image uniformity and
the sensitivity of the system. Some test phantoms also include targets of varying backscatter
values and sizes to assess the contrast detectability. These are the basic targets included in a
test phantom used to assess image quality for the general application of diagnostic
ultrasound. However, as ultrasound imaging has moved into many diagnostic, and some
interventional fields, it is important to assess the efficacy of the test parameters for specific
clinical applications. It is important to identify the technical measures which will have the
best correlation with clinically relevant parameters of quality and thus, the greatest impact
on clinical outcomes and which pose the greatest risk if they change.

A further

consideration is whether it is possible to measure all clinical measures of quality directly and
if not, how can this risk be controlled in the QA process. The growth of technologies has
surpassed the production of new test phantoms and test protocols, and it is important to be
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proactive in the management of QA programmes to ensure that equipment is robustly
interrogated to guarantee that systems are operating at an optimum level of quality [10].

Table 3 presents the suppliers of quality assurance test phantoms, with details of the
specific models that are compatible a TRUS probe.

There have also been a number of test phantoms developed by research groups for quality
assurance of trans-rectal ultrasound systems, for the evaluation of specific parameters;
from volume and geometry accuracy to more complex image artefacts that may cause
inaccurate seed placement and sub optimal treatment outcomes.
The volume of the prostate is an important factor in treatment planning for dose
determination and distribution. Drever et al. 2007 describes a simple agarose based test
phantom developed for volume measurements that can be used for routine daily QA of
volume accuracy. The nature of the brachytherapy procedure requires accurate needle
insertion and seed placement to ensure optimal dose delivery and treatment outcomes.
Goldstein et al. 2002 [30] designed a simple yet effective test phantom of ethylene and
glycerol, that can be used to validate each TRUS probe to ensure that the needle grid used
during the procedure and the overlay grid displayed on the ultrasound system, are correctly
aligned. Ryu et al. 2012 [31] describes a custom-built agar based test phantom, designed
from clinical CT prostate data, used to examine seed placement accuracy, in particular for
larger prostates. During the prostate brachytherapy procedure, the needles are inserted
into the prostate perpendicular to the transverse ultrasound beam and as such there can be
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errors in needle tip localisation and seed placement, as well as side lobes that can cause
further issues with localisation. Peikari et al.2012 [32] descried a Wire-Bridge test phantom
that allows for elevation beamwidth measurements to examine the uncertainties associated
with localisation. In a study by Sandhu et al. 2010 [26], the improvements of tissue harmonic
imagining over B-mode imagining for the application of ultrasound guided prostate
brachytherapy were investigated for a number of the system parameters resolution,
geometric accuracy, depth of penetration, dead zone, signal-to-noise ratio and tissue-toclutter ratio, to compare the two modes using an in house test phantom made from
homogenized milk based Tissue mimicking material. As the patient pathway for prostate
cancer treatment usually requires a multimodality approach to the diagnostic imaging
employed it is advantageous to have a test phantom that can be used for cross modality
validation of all of the diagnostic imaging employed. Hungr et al. 2012 described a test
phantom that can be used with TRUS CT and MRI that also exhibits the deformability
characteristics of tissue.

Phantoms for TRUS Brachytherapy

Presented in figure 1 are some of the commercially available test phantoms recommended
for quality assurance of TRUS systems. Although some test phantoms have evolved and
designed a cavity to insert the TRUS probe, they have not been modified to include clinically
applicable test objects of relevant size, depth or contrast.

Recommendations from the AAPM task group report 128 [2] include some important design
elements for a TRUS test phantom, such as a prostate target and the clinically relevant
13

orientation. However, this report recommends a high contrast prostate target relevant to
background and this does not mimic the clinical situation. A high contrast target is available
in a currently available CIRS training test phantom, but as shown in figure 2 the contrast is
not applicable. The contrast resolution is vital in the TRUS imaging performed during
brachytherapy; the delineation of the prostate, and therefore the ability to accurately assess
the volume is critical to the procedure.

A suitable test phantom to be used in Ultrasound imaging will have a tissue mimicking
material (TMM) with acoustic properties and mechanical properties of the tissue as close to
that of soft tissue. Investigations into suitable TMM for US began in the late 1970’s using gel
and served as a platform for future work [33]. The use of organic materials such as animal
tissues and foodstuffs as suitable TMM, have also been investigated. The TMM acoustic
properties need to be as close to that of the relevant soft tissue as possible. There are 3
essential acoustic parameters of a successful TMM; speed of sound (SOS), attenuation
coefficient and backscatter [34]. The acoustic properties of prostate tissue have been
reported in the literature with attenuation value of 1.86±0.14 dB/mm and acoustic velocity
of 1614±30 m/s in normal prostate and 1.42±0.08 dB/mm and 1584±12 m/s in prostate
cancer respectively [35]. International bodies such as the IEC and the AIUM have specified
the acoustic velocity 1540m/s and attenuation as 0.5 & 0.7 dB/cm/Mhz. The advantages and
disadvantages of a range of tissue mimicking materials are discussed in the literature; in
relation to their acoustic properties and suitability to specific applications [36]. Table 4,
adapted from Culjat et al.[36] and Browne et al. [37], presents the acoustic velocity and
attenuation for a number of these materials.

14

The materials that are in the commercially manufactured test phantoms and the IEC Agar
TMM [47] which can be produced for custom and research phantoms, have been
investigated and acoustically characterised to determine their stability and limitations in the
context of quality assurance testing [37]. Browne et al. investigated the effects of
temperature and frequency dependency of the materials. These are important
considerations for a quality assurance phantom; a test phantom should be stable and only
changes in the ultrasound system performance should be highlighted at the quality
assurance testing. Changes in the acoustic properties, specifically the velocity, can cause
distortion in distance measurements and this has the potential to effect resolution
measurements [48][49].
As well as the acoustic properties, the mechanical properties of a TMM should be
considered when designing a suitable test phantom. Professional bodies do not recommend
specific mechanical properties for suitable TMM in quality assurance test phantoms. Shear
wave elastography is an ultrasound imaging technique that aims to quantitatively image a
tissue to determine the stiffness, as differences in the mechanical properties, such as the
compressibility, can be an indication of disease in tissue [50]. This property of the tissue is
the Young’s modulus and indicates the stiffness if the tissue. It indicates the relationship
between stress and strain, and is a pressure measured in kPa. In the prostate, it has been
shown that cancerous tissue has a greater Young’s modulus than that of healthy tissue
[51][52][53]; indicating that diseased tissue is stiffer than that of healthy tissue. This type of
stiffness can be matched in TMM by varying the concentration of the components in the
material. Cournane et al. [54] reviewed quality control test phantoms for ultrasound
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elastography and proposed mechanical properties for TMM to mimic various tissues in the
body. The proposed range for prostate tissue was 15 kPa, with malignancy between 10-15
kPa.
The longevity of the material used in a test phantom also needs to be considered.
Economically it is favourable for a test phantom to remain stable for a long period of time.
The shelf life of a phantom should be clear and should be considered when acquiring a test
phantom. Imaging a test phantom, before quality assurance tests are performed, using
another modality such as CT, can be a convenient method to examine any changes in the
phantom itself. Another indication of degradation is the weight of the test phantom. The
stability of the test phantom overtime will be important in consistency in quality assurance
testing; deterioration should be due to US system performance and not degradation of the
test phantom.
There are many factors that need to be considered in the design of a suitable test phantom
for the application of TRUS imaging for the application of brachytherapy. The targets
included should be designed to assess all aspects of the image quality, and the test phantom
needs to be constructed to effectively assess each transducer view used during the
procedure.

Discussion
the American Association of Physics in Medicine (AAPM) [2] offer guidance and specific
recommendations for quality assurance of TRUS systems used in brachytherapy procedures.
However, it is important to consider if each of the conventional test parameters assess
relevant features of image quality of a TRUS image and how to conduct the tests to ensure
that any degradation in the image quality is detected. The test parameters and test
16

phantoms have been presented and will now be discussed in terms of their relevance and
efficacy to this application of TRUS image quality.
The resolution of a TRUS image for prostate brachytherapy is important for boundary
detection, however the AAPM do not provide any recommendations for the measurement
of the slice thickness. The partial volume effect has the potential to cause misdiagnosis,
where cystic structures are not represented in the image due to an accumulation of scan
lines when the beam width is reduced. This can cause fill-in of the cyst, either partially or
totally in the image [55]. Small spherical lesions with varying contrast could be incorporated
into a clinically applicable test phantom. These “cysts” could be used to assess the slice
thickness as well as the axial and lateral resolution and could also be used to determine the
contrast detectability of the system if targets of varying contrast were included.
The sensitivity of the system will impact the visualization the prostate [2], and the ability of
the user to delineate the prostate from surrounding tissue. Assessing the low contrast
detectability of the system will allow for a relevant measure of the sensitivity of a system
used in TRUS brachytherapy. This test design should be considered for both the
methodology of the test procedure and the design of the test object. Targets with small
variations in contrast, which are clinically relevant at assorted sizes, would be ideal targets
in a brachytherapy test phantom to assess ultrasound image quality.
A prostate mimicking target is of paramount importance in the design of a test phantom for
a prostate brachytherapy ultrasound test phantom. A low contrast prostate target of
known, clinically applicable dimensions could be used to assess area and volume
measurements.
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The grid that is used during the procedure to align the needles that introduce the sources
into the prostate under TRUS image guidance should also be evaluated. The physical
alignment tool and electronic grid alignment should be verified with a suitable set of targets
in the test phantom; a grid of moderate to high contrast targets that can verify the spatial
accuracy of the alignment.
A test phantom for this application of ultrasound should be designed with the prostate
brachytherapy procedure in mind, considering probe orientation and operation, with
attention to include both sagittal and transverse views. The TRUS probe should be
introduced into the test phantom through a cavity in the appropriate configuration, i.e. the
test phantom should be above the probe. The depths of the structures and targets inside
the test phantom are an important consideration. Clinically the configuration of the probe in
the rectal cavity gives an optimum imaging location; with only a few millimetres of rectal
wall separating the probe from the cavity. This should be emulated in a test phantom when
designing and positioning prostate targets. Both views on the probe are used during the
procedure, at both biopsy and interventional stages. The sagittal array is used to assess the
length of the prostate and the transverse array is used to assess the width and height of the
gland. This can be problematic with traditional test phantoms that generally incorporate an
imaging plane designed for linear array transducer, and can impede the evaluation of the
transverse field of view. A test phantom with an imagining window or probe holder that will
allow for orientation of the probe to examine the image quality of both sagittal and
transverse transducer arrays in a reliable manner would facilitate a more reproducible
quality assurance programme.
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Quality assurance recommendations for a testing protocol and an application specific test
phantom for the ultrasound systems used in TRUS guided prostate brachytherapy are
presented in table 5.
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Conclusion
Trans-rectal ultrasound is a valuable tool in the diagnosis and treatment of prostate cancer.
It is important to monitor system performance and perform regular quality assurance that is
specific to this application. This includes a regime of tests that are designed to capture
indicators of image quality degradation, and a test phantom that can effectively detect
these adverse anomalies in the image. The design should be suitable for the end user in a
hospital environment without compromising the clinical relevance.
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